{
    "clinical_study": {
        "@rank": "127678", 
        "arm_group": {
            "arm_group_label": "Diagnostic (18F FPPRGD2 PET/CT)", 
            "arm_group_type": "Experimental", 
            "description": "Patients undergo 18F FPPRGD2 PET/CT imaging at baseline, 1 week, and 6 weeks and 18F FDG PET/CT at baseline and 6 weeks."
        }, 
        "brief_summary": {
            "textblock": "This phase I/II trial studies fluorine 18 2-fluoropropionyl-labeled pegylated dimeric\n      arginine-glycine-aspartic acid (RGD) peptide (18F FPPRGD2) positron emission tomography\n      (PET)/computed tomography (CT) in predicting early response in patients with cancer\n      receiving anti-angiogenesis therapy. Diagnostic procedures, such as 18F FPPRGD2 PET/CT, may\n      be a less invasive method of finding cancer early and determining response to treatment"
        }, 
        "brief_title": "18F FPPRGD2 Positron Emission Tomography/Computed Tomography in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy", 
        "completion_date": {
            "#text": "March 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Adult Giant Cell Glioblastoma", 
            "Adult Glioblastoma", 
            "Adult Gliosarcoma", 
            "Male Breast Cancer", 
            "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma", 
            "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", 
            "Recurrent Adult Brain Tumor", 
            "Recurrent Basal Cell Carcinoma of the Lip", 
            "Recurrent Breast Cancer", 
            "Recurrent Colon Cancer", 
            "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", 
            "Recurrent Hypopharyngeal Cancer", 
            "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", 
            "Recurrent Laryngeal Cancer", 
            "Recurrent Lip and Oral Cavity Cancer", 
            "Recurrent Lymphoepithelioma of the Nasopharynx", 
            "Recurrent Lymphoepithelioma of the Oropharynx", 
            "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", 
            "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", 
            "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", 
            "Recurrent Nasopharyngeal Cancer", 
            "Recurrent Non-small Cell Lung Cancer", 
            "Recurrent Oropharyngeal Cancer", 
            "Recurrent Pancreatic Cancer", 
            "Recurrent Paranasal Sinus and Nasal Cavity Cancer", 
            "Recurrent Rectal Cancer", 
            "Recurrent Renal Cell Cancer", 
            "Recurrent Salivary Gland Cancer", 
            "Stage IIIA Breast Cancer", 
            "Stage IIIA Non-small Cell Lung Cancer", 
            "Stage IIIB Breast Cancer", 
            "Stage IIIB Non-small Cell Lung Cancer", 
            "Stage IIIC Breast Cancer", 
            "Stage IV Breast Cancer", 
            "Stage IV Non-small Cell Lung Cancer", 
            "Stage IV Pancreatic Cancer", 
            "Stage IV Renal Cell Cancer", 
            "Stage IVA Colon Cancer", 
            "Stage IVA Rectal Cancer", 
            "Stage IVA Salivary Gland Cancer", 
            "Stage IVB Colon Cancer", 
            "Stage IVB Salivary Gland Cancer", 
            "Stage IVC Salivary Gland Cancer", 
            "Tongue Cancer", 
            "Unspecified Adult Solid Tumor, Protocol Specific"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Brain Neoplasms", 
                "Breast Neoplasms", 
                "Carcinoma", 
                "Colonic Neoplasms", 
                "Laryngeal Neoplasms", 
                "Rectal Neoplasms", 
                "Carcinoma, Basal Cell", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Carcinoma, Renal Cell", 
                "Carcinoma, Squamous Cell", 
                "Carcinoma, Adenoid Cystic", 
                "Glioblastoma", 
                "Granuloma", 
                "Lung Neoplasms", 
                "Mouth Neoplasms", 
                "Pancreatic Neoplasms", 
                "Papilloma", 
                "Tongue Neoplasms", 
                "Oropharyngeal Neoplasms", 
                "Nasopharyngeal Neoplasms", 
                "Hypopharyngeal Neoplasms", 
                "Carcinoma, Mucoepidermoid", 
                "Esthesioneuroblastoma, Olfactory", 
                "Papilloma, Inverted", 
                "Gliosarcoma", 
                "Head and Neck Neoplasms", 
                "Neoplasms, Unknown Primary", 
                "Salivary Gland Neoplasms", 
                "Lip Neoplasms", 
                "Breast Neoplasms, Male"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Evaluate 18F FPPRGD2 PET/CT for prediction and early assessment of response to\n      anti-angiogenesis therapy in patients with non-small cell lung cancer (NSCLC), breast\n      cancer, glioblastoma multiforme (GBM) and other cancers.\n\n      OUTLINE:\n\n      Patients undergo 18F FPPRGD2 PET/CT imaging at baseline, 1 week, and 6 weeks and 18F FDG\n      PET/CT at baseline and 6 weeks.\n\n      After completion of study imaging, patients are followed up at 12 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provides written informed consent\n\n          -  Diagnosed with advanced NSCLC, breast cancer, GBM or other cancers (such as head and\n             neck, colorectal, pancreatic, renal cancers); patients will undergo anti-angiogenesis\n             treatment\n\n          -  Able to remain still for duration of each imaging procedure (about one hour)\n\n        Exclusion Criteria:\n\n          -  Pregnant or nursing"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01806675", 
            "org_study_id": "VARIMG0002", 
            "secondary_id": "NCI-2013-00535"
        }, 
        "intervention": [
            {
                "arm_group_label": "Diagnostic (18F FPPRGD2 PET/CT)", 
                "description": "Undergo 18F FDG PET/CT", 
                "intervention_name": "fludeoxyglucose F 18", 
                "intervention_type": "Radiation", 
                "other_name": [
                    "18FDG", 
                    "FDG"
                ]
            }, 
            {
                "arm_group_label": "Diagnostic (18F FPPRGD2 PET/CT)", 
                "description": "Undergo 18F FPPRGD2 PET/CT", 
                "intervention_name": "2-fluoropropionyl-labeled pegylated dimeric RGD peptide", 
                "intervention_type": "Radiation", 
                "other_name": [
                    "104150", 
                    "18F-FPPRGD2", 
                    "[18F] FPPRGD2", 
                    "fluorine 18 ((18)F) FPPRGD2", 
                    "PEG3-E[c(RGDyk)]2"
                ]
            }, 
            {
                "arm_group_label": "Diagnostic (18F FPPRGD2 PET/CT)", 
                "description": "Undergo 18F FPPRGD2 PET/CT", 
                "intervention_name": "positron emission tomography", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "FDG-PET", 
                    "PET", 
                    "PET scan", 
                    "tomography, emission computed"
                ]
            }, 
            {
                "arm_group_label": "Diagnostic (18F FPPRGD2 PET/CT)", 
                "description": "Undergo 18F FPPRGD2 PET/CT", 
                "intervention_name": "computed tomography", 
                "intervention_type": "Procedure", 
                "other_name": "tomography, computed"
            }, 
            {
                "arm_group_label": "Diagnostic (18F FPPRGD2 PET/CT)", 
                "description": "Undergo 18F FDG PET/CT", 
                "intervention_name": "positron emission tomography", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "FDG-PET", 
                    "PET", 
                    "PET scan", 
                    "tomography, emission computed"
                ]
            }, 
            {
                "arm_group_label": "Diagnostic (18F FPPRGD2 PET/CT)", 
                "description": "Undergo 18F FDG PET/CT", 
                "intervention_name": "computed tomography", 
                "intervention_type": "Procedure", 
                "other_name": "tomography, computed"
            }, 
            {
                "arm_group_label": "Diagnostic (18F FPPRGD2 PET/CT)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Arginyl-glycyl-aspartic acid"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Stanford", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94305"
                }, 
                "name": "Stanford University Cancer Institute"
            }, 
            "investigator": {
                "last_name": "Sanjiv Gambhir", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I/II 18F FPPRGD2 PET/CT Imaging of \u03b1v\u03b23 Integrins Expression as a Biomarker of Angiogenesis", 
        "overall_contact": {
            "email": "euodia@stanford.edu", 
            "last_name": "Jonathan Euodia", 
            "phone": "650-723-7419"
        }, 
        "overall_official": {
            "affiliation": "Stanford University", 
            "last_name": "Sanjiv Gambhir", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Response to treatment is based on the change in PET uptake, change in CT tumor size, PET European Organization for Research and Treatment of Cancer (EORTC) response criteria, and CT Response Evaluation Criteria In Solid Tumors (RECIST) response criteria. Each of the four response criteria will be dichotomized into responding or non-responding to treatment. The Mann-Whitney test and logistic regression of response/non-response will be performed.", 
            "measure": "Change in maximum standard uptake values (SUVmax) on 18F FPPRGD2 and 18F FDG PET", 
            "safety_issue": "No", 
            "time_frame": "From baseline up to 6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01806675"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "For each SUV measure patients will be divided into two groups based on whether their SUV uptake is above or below the median. Kaplan-Meir curves for the two groups will be plotted and a log-rank test for difference in PFS will be performed. A Cox proportional-hazards regression of PFS on group will be performed.", 
            "measure": "Progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "Up to 1 year"
        }, 
        "source": "Stanford University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Stanford University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}